The CCAAT/Enhancer-Binding Protein Family: Its Roles in MDSC Expansion and Function

Immunosuppressive cells have been highlighted in research due to their roles in tumor progression and treatment failure. Myeloid-derived suppressor cells (MDSCs) are among the major immunosuppressive cell populations in the tumor microenvironment, and transcription factors (TFs) are likely involved...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 10; p. 1804
Main Authors Wang, Wenxin, Xia, Xueli, Mao, Lingxiang, Wang, Shengjun
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 31.07.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Immunosuppressive cells have been highlighted in research due to their roles in tumor progression and treatment failure. Myeloid-derived suppressor cells (MDSCs) are among the major immunosuppressive cell populations in the tumor microenvironment, and transcription factors (TFs) are likely involved in MDSC expansion and activation. As key regulatory TFs, members of the CCAAT/enhancer-binding protein (C/EBP) family possibly modulate many biological processes, including cell growth, differentiation, metabolism, and death. Current evidence suggests that C/EBPs maintain critical regulation of MDSCs and are involved in the differentiation and function of MDSCs within the tumor microenvironment. To better understand the MDSC-associated transcriptional network and identify new therapy targets, we herein review recent findings about the C/EBP family regarding their participation in the expansion and function of MDSCs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology
Reviewed by: Nagarkatti Prakash, University of South Carolina, United States; Ilaria Marigo, Istituto Oncologico Veneto (IRCCS), Italy
Edited by: Jan Fric, International Clinical Research Center (FNUSA-ICRC), Czechia
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2019.01804